Download Image
    
Share
  
Post
Dalcetrapib for COVID-19
1 study with 208 patients
Hospital Icon Control
Hospital Icon Dalcetrapib Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Dalcetrapib studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -134% Mortality -134% Hospitalization -37% RCTs -134% Early -134% Favorsdalcetrapib Favorscontrol
May 17
2021
 Kallend et al., NCT04676867 A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
134% higher mortality (p=1), 134% higher ventilation (p=1), 139% higher need for oxygen therapy (p=0.68), and 37% higher hospitalization (p=1). RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.